Logo ČVUT
CZECH TECHNICAL UNIVERSITY IN PRAGUE
STUDY PLANS
2024/2025

Health Technology Assessment

The course is not on the list Without time-table
Code Completion Credits Range Language
F7PMSHZT Z,ZK 4 2P+2S Czech
Vztahy:
In order to register for the course F7PMSEAZ, the student must have successfully completed the course F7PMSHZT.
Garant předmětu:
Lecturer:
Tutor:
Supervisor:
Department of Biomedical Technology
Synopsis:
Requirements:

Seminar: active participation in the seminar, test

Exam: written test with open questions as a door-keeper to the oral exam; the result (passed/failed) and final grade of the exam depend on the oral part of the exam

Syllabus of lectures:

•Introduction to HTA, the role of HTA, historical overview. HTA definition: specification of HTA, basic lines of HTA, the perspective of HTA studies. Scope of HTA. Utilization of HTA in decisions about reimbursement of a new technology. Utilization of HTA for strategic decisions in hospitals. Separation of assessment and decision-making.

•Evidence based medicine. Quality of information sources for EBM. Literature reviews: technique of literature reviews, databases of publications and research results, Cochrane Institute. Meta-analysis and its techniques. Data sources: international databases, Institute of Health Information and Statistics of the Czech Republic, retrospective data from healthcare providers and payers.

•Outcomes in the field of HTA: how to collect, process, calculate with them. Types used in HTA.

•Multiple-criteria methods for figuring out the outcomes. Measurement of quality of life: QALY, DALY, LYG, various ways how to measure QoL, generic and specific questionnaires, time trade-off, standard gamble.

•Costs and resources of cost data: direct medical costs, direct non-medical costs. Costs and resources of cost data: Indirect costs, intangible costs.

•Cost analyses: CMA, CEA, CUA, ICER, CBA, CIA, CCA. Economic-theoretical foundations of cost analyses. Modelling in HTA. Sensitivity analysis.

•Core model. NICE model. HTA for pharmaceuticals.

•Utilization of HTA in decision-making about reimbursement of a new technology. Inclusion of a new technology in the reimbursement system. Disinvestment. Budget-impact analysis (BIA). Willingness to pay. Threshold values and their introduction. Individual thresholds.

•HTA for medical devices. Suitable analyses, the assessment process. HB-HTA: Utilization of HTA at a single-hospital level.

•Organization and collaboration in HTA: Institutions at a national level, transfer of results between different healthcare systems. International societies and organizations. Ethics and HTA.

Syllabus of tutorials:

•Introduction to HTA, the role of HTA, historical overview. HTA definition: specification of HTA, basic lines of HTA, the perspective of HTA studies. Scope of HTA. Utilization of HTA in decisions about reimbursement of a new technology. Utilization of HTA for strategic decisions in hospitals. Separation of assessment and decision-making.

•Evidence based medicine. Quality of information sources for EBM. Literature reviews: technique of literature reviews, databases of publications and research results, Cochrane Institute. Meta-analysis and its techniques. Data sources: international databases, Institute of Health Information and Statistics of the Czech Republic, retrospective data from healthcare providers and payers.

•Outcomes in the field of HTA: how to collect, process, calculate with them. Types used in HTA.

•Multiple-criteria methods for figuring out the outcomes. Measurement of quality of life: QALY, DALY, LYG, various ways how to measure QoL, generic and specific questionnaires, time trade-off, standard gamble.

•Costs and resources of cost data: direct medical costs, direct non-medical costs. Costs and resources of cost data: Indirect costs, intangible costs.

•Cost analyses: CMA, CEA, CUA, ICER, CBA, CIA, CCA. Economic-theoretical foundations of cost analyses. Modelling in HTA. Sensitivity analysis.

•Core model. NICE model. HTA for pharmaceuticals.

•Utilization of HTA in decision-making about reimbursement of a new technology. Inclusion of a new technology in the reimbursement system. Disinvestment. Budget-impact analysis (BIA). Willingness to pay. Threshold values and their introduction. Individual thresholds.

•HTA for medical devices. Suitable analyses, the assessment process. HB-HTA: Utilization of HTA at a single-hospital level.

•Organization and collaboration in HTA: Institutions at a national level, transfer of results between different healthcare systems. International societies and organizations. Ethics and HTA.

Study Objective:
Study materials:

Required:

[1].GOODMAN, Clifford S.: HTA101. Introduction to Health Technology Assessment. The Lewin Group, Virginia, 2014. (Volně dostupné z http://www.nlm.nih.gov/nichsr/hta101/HTA_101_FINAL_7-23-14.pdf)

[2].BRENT, Robert J. Cost-benefit analysis and health care evaluations. Northhampton, MA: Edward Elgar, 2003. ISBN 978-1840648447.

[3].SCHÖFFSKI, Oliver. a Johann-Matthias SCHULENBURG. Gesundheitsökonomische Evaluationen. 4., vollständig überarb. Aufl. Berlin: Springer, 2012. ISBN 978-3-642-21699-2.

Recommended:

www.czechhta.cz

Note:
Further information:
No time-table has been prepared for this course
The course is a part of the following study plans:
Data valid to 2024-06-16
Aktualizace výše uvedených informací naleznete na adrese https://bilakniha.cvut.cz/en/predmet5816406.html